OSE Immunotherapeutics SA
PAR:OSE

Watchlist Manager
OSE Immunotherapeutics SA Logo
OSE Immunotherapeutics SA
PAR:OSE
Watchlist
Price: 9.9 EUR -1.59% Market Closed
Market Cap: 215.4m EUR
Have any thoughts about
OSE Immunotherapeutics SA?
Write Note

Intrinsic Value

The intrinsic value of one OSE stock under the Base Case scenario is 28.42 EUR. Compared to the current market price of 9.9 EUR, OSE Immunotherapeutics SA is Undervalued by 65%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

OSE Intrinsic Value
28.42 EUR
Undervaluation 65%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
OSE Immunotherapeutics SA

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for OSE cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about OSE?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about OSE Immunotherapeutics SA

Provide an overview of the primary business activities
of OSE Immunotherapeutics SA.

What unique competitive advantages
does OSE Immunotherapeutics SA hold over its rivals?

What risks and challenges
does OSE Immunotherapeutics SA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for OSE Immunotherapeutics SA.

Provide P/S
for OSE Immunotherapeutics SA.

Provide P/E
for OSE Immunotherapeutics SA.

Provide P/OCF
for OSE Immunotherapeutics SA.

Provide P/FCFE
for OSE Immunotherapeutics SA.

Provide P/B
for OSE Immunotherapeutics SA.

Provide EV/S
for OSE Immunotherapeutics SA.

Provide EV/GP
for OSE Immunotherapeutics SA.

Provide EV/EBITDA
for OSE Immunotherapeutics SA.

Provide EV/EBIT
for OSE Immunotherapeutics SA.

Provide EV/OCF
for OSE Immunotherapeutics SA.

Provide EV/FCFF
for OSE Immunotherapeutics SA.

Provide EV/IC
for OSE Immunotherapeutics SA.

Show me price targets
for OSE Immunotherapeutics SA made by professional analysts.

What are the Revenue projections
for OSE Immunotherapeutics SA?

How accurate were the past Revenue estimates
for OSE Immunotherapeutics SA?

What are the Net Income projections
for OSE Immunotherapeutics SA?

How accurate were the past Net Income estimates
for OSE Immunotherapeutics SA?

What are the EPS projections
for OSE Immunotherapeutics SA?

How accurate were the past EPS estimates
for OSE Immunotherapeutics SA?

What are the EBIT projections
for OSE Immunotherapeutics SA?

How accurate were the past EBIT estimates
for OSE Immunotherapeutics SA?

Compare the revenue forecasts
for OSE Immunotherapeutics SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of OSE Immunotherapeutics SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of OSE Immunotherapeutics SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of OSE Immunotherapeutics SA compared to its peers.

Compare the P/E ratios
of OSE Immunotherapeutics SA against its peers.

Discuss the investment returns and shareholder value creation
comparing OSE Immunotherapeutics SA with its peers.

Analyze the financial leverage
of OSE Immunotherapeutics SA compared to its main competitors.

Show all profitability ratios
for OSE Immunotherapeutics SA.

Provide ROE
for OSE Immunotherapeutics SA.

Provide ROA
for OSE Immunotherapeutics SA.

Provide ROIC
for OSE Immunotherapeutics SA.

Provide ROCE
for OSE Immunotherapeutics SA.

Provide Gross Margin
for OSE Immunotherapeutics SA.

Provide Operating Margin
for OSE Immunotherapeutics SA.

Provide Net Margin
for OSE Immunotherapeutics SA.

Provide FCF Margin
for OSE Immunotherapeutics SA.

Show all solvency ratios
for OSE Immunotherapeutics SA.

Provide D/E Ratio
for OSE Immunotherapeutics SA.

Provide D/A Ratio
for OSE Immunotherapeutics SA.

Provide Interest Coverage Ratio
for OSE Immunotherapeutics SA.

Provide Altman Z-Score Ratio
for OSE Immunotherapeutics SA.

Provide Quick Ratio
for OSE Immunotherapeutics SA.

Provide Current Ratio
for OSE Immunotherapeutics SA.

Provide Cash Ratio
for OSE Immunotherapeutics SA.

What is the historical Revenue growth
over the last 5 years for OSE Immunotherapeutics SA?

What is the historical Net Income growth
over the last 5 years for OSE Immunotherapeutics SA?

What is the current Free Cash Flow
of OSE Immunotherapeutics SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for OSE Immunotherapeutics SA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
OSE Immunotherapeutics SA

Current Assets 85.8m
Cash & Short-Term Investments 75.7m
Receivables 7.6m
Other Current Assets 2.5m
Non-Current Assets 55.1m
Long-Term Investments 6.1m
PP&E 3.6m
Intangibles 45.2m
Other Non-Current Assets 194k
Current Liabilities 17.4m
Accounts Payable 8.3m
Accrued Liabilities 2.2m
Other Current Liabilities 6.8m
Non-Current Liabilities 42.1m
Long-Term Debt 40m
Other Non-Current Liabilities 2.1m
Efficiency

Earnings Waterfall
OSE Immunotherapeutics SA

Revenue
83.4m EUR
Operating Expenses
-29.5m EUR
Operating Income
53.9m EUR
Other Expenses
-7.9m EUR
Net Income
46m EUR

Free Cash Flow Analysis
OSE Immunotherapeutics SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

OSE Profitability Score
Profitability Due Diligence

OSE Immunotherapeutics SA's profitability score is 46/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional Revenue Growth Forecast
Exceptional ROE
Exceptional ROIC
46/100
Profitability
Score

OSE Immunotherapeutics SA's profitability score is 46/100. The higher the profitability score, the more profitable the company is.

OSE Solvency Score
Solvency Due Diligence

OSE Immunotherapeutics SA's solvency score is 68/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Negative Net Debt
68/100
Solvency
Score

OSE Immunotherapeutics SA's solvency score is 68/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

OSE Price Targets Summary
OSE Immunotherapeutics SA

Wall Street analysts forecast OSE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for OSE is 14.5 EUR with a low forecast of 10.91 EUR and a high forecast of 22.37 EUR.

Lowest
Price Target
10.91 EUR
10% Upside
Average
Price Target
14.5 EUR
47% Upside
Highest
Price Target
22.37 EUR
126% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for OSE?

Click here to dive deeper.

Dividends

OSE Immunotherapeutics SA
does not pay dividends
Shareholder Yield

Current shareholder yield for OSE is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

OSE Immunotherapeutics SA Logo
OSE Immunotherapeutics SA

Country

France

Industry

Biotechnology

Market Cap

215.5m EUR

Dividend Yield

0%

Description

OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

Contact

PAYS DE LA LOIRE
Nantes
22, boulevard Benoni Goullin
+33228291010.0
ose-immuno.com

IPO

2015-03-30

Employees

61

Officers

General Director, CEO, Scientific Director & Director
Dr. Nicolas Poirier Ph.D.
Founder & Director of Development & Strategy
Dr. Anne-Marie Dominique Costantini M.D.
CFO, Administrative & Financial Director and Employee Shareholder Representative Director
Ms. Anne-Laure Autret-Cornet
Consultant
Mr. Alexis Peyroles
Medical Director
Dr. Alain Chatelin M.D.
Chief Medical Officer Immuno-Oncology
Bérangère Vasseur M.D.
Show More
Chief Commercial Officer
Mr. Julien Perrier
Chief Regulatory Officer
Ms. Linda Lebon M.Sc.
Head of Clinical Development
Dr. Silvia Comis M.D.
Chief Business Officer
Mr. Jean-Jacques Mention
Show Less

See Also

Discover More
What is the Intrinsic Value of one OSE stock?

The intrinsic value of one OSE stock under the Base Case scenario is 28.42 EUR.

Is OSE stock undervalued or overvalued?

Compared to the current market price of 9.9 EUR, OSE Immunotherapeutics SA is Undervalued by 65%.

Back to Top